NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 10/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Aravive Stock (NASDAQ:ARAV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aravive alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aravive, Inc. was a clinical-stage biotechnology company focused on developing therapies for serious cancers and fibrotic diseases. The company’s lead product candidate was batiraxcept, also known as AVB-500, a recombinant fusion protein designed to inhibit the GAS6-AXL signaling pathway, which is associated with tumor growth, metastasis, treatment resistance and immune suppression. Aravive evaluated batiraxcept in clinical studies for conditions including platinum-resistant ovarian cancer and renal cell carcinoma. The company’s research programs were intended to address cancers with limited treatment options, using a therapeutic approach designed to interfere with signals that support cancer-cell survival and progression. The company was headquartered in Houston, Texas, and operated primarily as a U.S.-based biotechnology developer. Gail McIntyre, Ph.D., served as Aravive’s president and chief executive officer during its development of batiraxcept. In 2023, Aravive reported that a late-stage study of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint and subsequently announced plans to wind down operations and explore strategic alternatives.AI Generated. May Contain Errors. Read More Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARAV Stock News HeadlinesOut-of-state companies win grants for trials at Houston's MD Anderson Cancer CenterNovember 27, 2024 | bizjournals.comAdial Pharmaceuticals Appoints Vinay Shah To Succeed Joseph Truluck As CFONovember 5, 2024 | markets.businessinsider.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 16 at 1:00 AM | Porter & Company (Ad)Global Automated Cell Culture Market to Exhibit Significant Growth at a CAGR of ~7% by 2030 | DelveInsightOctober 17, 2024 | finance.yahoo.comHouston-based health supplements co. to delist from Nasdaq, dissolveOctober 3, 2024 | bizjournals.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares SlideJanuary 18, 2024 | msn.comSee More Headlines ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? Aravive's stock was trading at $0.0401 at the beginning of the year. Since then, ARAV shares have increased by 0.0% and is now trading at $0.0401. How were Aravive's earnings last quarter? Aravive, Inc (NASDAQ:ARAV) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The company had revenue of $2.41 million for the quarter, compared to analysts' expectations of $2.36 million. When did Aravive IPO? Aravive (ARAV) raised $120 million in an initial public offering on Thursday, March 20th 2014. The company issued 6,000,000 shares at $19.00-$21.00 per share. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include Sorrento Therapeutics (SRNE), Ocugen (OCGN), X4 Pharmaceuticals (XFOR), NVIDIA (NVDA), Aptose Biosciences (APTO), Atossa Genetics (ATOS) and Black Diamond Therapeutics (BDTX). Company Calendar Last Earnings10/27/2021Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARAV CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees20Year Founded2008Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.99 million Price / Sales0.42 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares73,563,000Free FloatN/AMarket Cap$2.95 million OptionableNo Data Beta2.19 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ARAV) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredMy next big call (under $1)Bitcoin is down. Fear is high. Most investors are sitting on their hands. That's exactly when my biggest winne...Crypto 101 Media | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
